<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - DESMOPRESSIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>DESMOPRESSIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Diabetes insipidus, treatment</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection or by intravenous injection or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 100 micrograms 3 times a day; maintenance 100&#8211;200 micrograms 3 times a day; usual dose 0.2&#8211;1.2 mg daily.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 60 micrograms 3 times a day, adjusted according to response; usual dose 40&#8211;240 micrograms 3 times a day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                10&#8211;40 micrograms daily in 1&#8211;2 divided doses.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                1&#8211;4 micrograms daily.</li>
              <li class="dose child"><strong>For children 1 month&#8211;1 year</strong><br/>
                Initially 10 micrograms 2&#8211;3 times a day, adjusted according to response; usual dose 30&#8211;150 micrograms daily.</li>
              <li class="dose child"><strong>For children 2&#8211;11 years</strong><br/>
                Initially 50 micrograms 2&#8211;3 times a day, adjusted according to response; usual dose 100&#8211;800 micrograms daily.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 100 micrograms 2&#8211;3 times a day, adjusted according to response; usual dose 0.2&#8211;1.2 mg daily.</li>
              <li class="dose child"><strong>For children 2&#8211;17 years</strong><br/>
                Initially 60 micrograms 3 times a day, adjusted according to response; usual dose 40&#8211;240 micrograms 3 times a day.</li>
              <li class="dose child"><strong>For children 1 month&#8211;1 year</strong><br/>
                Initially 2.5&#8211;5 micrograms 1&#8211;2 times a day, adjusted according to response.</li>
              <li class="dose child"><strong>For children 2&#8211;11 years</strong><br/>
                Initially 5&#8211;20 micrograms 1&#8211;2 times a day, adjusted according to response.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 10&#8211;20 micrograms 1&#8211;2 times a day, adjusted according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Primary nocturnal enuresis</span>,
            </h4>
            <p class="specificity"><span class="route">By sublingual administration</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;65 years</strong><br/>
                200 micrograms once daily, only increased to 400 micrograms if lower dose not effective; withdraw for at least 1 week for reassessment after 3 months, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration.</li>
              <li class="dose adult"><strong>For adults 18&#8211;65 years</strong><br/>
                120 micrograms once daily, increased if necessary to 240 micrograms once daily, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration, dose to be increased only if lower dose not effective, reassess after 3 months by withdrawing treatment for at least 1 week.</li>
              <li class="dose child"><strong>For children 5&#8211;17 years</strong><br/>
                200 micrograms once daily, only increased to 400 micrograms if lower dose not effective; withdraw for at least 1 week for reassessment after 3 months, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration.</li>
              <li class="dose child"><strong>For children 5&#8211;17 years</strong><br/>
                120 micrograms once daily, increased if necessary to 240 micrograms once daily, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration, dose to be increased only if lower dose not effective, reassess after 3 months by withdrawing treatment for at least 1 week.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Postoperative polyuria or polydipsia</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Dose to be adjusted according to urine osmolality.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Polyuria or polydipsia after hypophysectomy</span>,
            </h4>
            <p class="specificity"><span class="route">By sublingual administration</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Dose to be adjusted according to urine osmolality.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Diabetes insipidus, diagnosis (water deprivation test)</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                20 micrograms, limit fluid intake to 500 mL from 1 hour before to 8 hours after administration.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                2 micrograms for 1 dose, limit fluid intake to 500 mL from 1 hour before to 8 hours after administration.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Nocturia associated with multiple sclerosis (when other treatments have failed)</span>,
            </h4>
            <p class="specificity"><span class="route">By intranasal administration</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;65 years</strong><br/>
                10&#8211;20 micrograms once daily, to be taken at bedtime, dose not to be repeated within 24 hours, limit fluid intake from 1 hour before to 8 hours after administration.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Renal function testing</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                40 micrograms, empty bladder at time of administration and limit fluid intake to 500 mL from 1 hour before until 8 hours after administration to avoid fluid overload.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                2 micrograms, empty bladder at time of administration and restrict fluid intake to 500 mL from 1 hour before until 8 hours after administration to avoid fluid overload.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Mild to moderate haemophilia and von Willebrand&#8217;s disease</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion or by subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300 micrograms every 12 hours if required, one 150 microgram spray into each nostril, 30 minutes before surgery or when bleeding, dose may alternatively be repeated at intervals of at least 3 days, if self-administered.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                300 nanograms/kg for 1 dose, to be administered immediately before surgery or after trauma; may be repeated at intervals of 12 hours if no tachycardia.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Fibrinolytic response testing</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection or by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300 micrograms, blood to be sampled after 1 hour for fibrinolytic activity, one 150 microgram spray to be administered into each nostril.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                300 nanograms/kg for 1 dose, blood to be sampled after 20 minutes for fibrinolytic activity.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Lumbar-puncture-associated headache</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Desmopressin is an analogue of vasopressin.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Small oxytocic effect in third trimester; increased risk of pre-eclampsia.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Use with caution; antidiuretic effect may be reduced.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Cardiac insufficiency</li>
            <li>conditions treated with diuretics</li>
            <li>polydipsia in alcohol dependence</li>
            <li>psychogenic polydipsia</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Allergic reactions, emotional disturbance in children, epistaxis, fluid retention, headache, hyponatraemia (in more serious cases with convulsions) on administration without restricting fluid intake, nasal congestion, nausea, stomach pain, vomiting,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> rhinitis,
              </p>
        
            <section class="advice">
                <h3>Hyponatraemic convulsions</h3>
              <p> The risk of hyponatraemic convulsions can be minimised by keeping to the recommended starting doses and by avoiding concomitant use of drugs which increase secretion of vasopressin (e.g. tricyclic antidepressants).</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>
            <i>DDVAP</i>
            <tm tmtype="reg"/> and <i>Desmotabs</i>
            <tm tmtype="reg"/> tablets may be crushed.</p>
            </section>
            <section class="directionsForAdministration">
              <p>
            <i>DDAVP</i>
            <tm tmtype="reg"/> intranasal solution may be diluted with Sodium Chloride 0.9% to a concentration of 10&#8239;micrograms/mL.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">In children</h3>
              <p>Higher doses of <i>DDAVP</i>
            <tm tmtype="reg"/> by <i>intravenous infusion</i>, used in mild to moderate haemophilia and von Willebrand&#8217;s disease, may be diluted with 30&#8211;50&#8239;mL Sodium Chloride 0.9% intravenous infusion.</p>
            </section>
            <section class="directionsForAdministration">
              <p>
            <i>DDAVP</i>
            <tm tmtype="reg"/> injection may be administered orally.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">In children</h3>
              <p>For <i>intravenous infusion</i> (<i>Octim</i>
            <tm tmtype="reg"/>), dilute with 50&#8239;mL of Sodium Chloride 0.9% and give over 20 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>DDVAP</i>
            <tm tmtype="reg"/>, <i>Octim</i>
            <tm tmtype="reg"/>), give intermittently in Sodium chloride 0.9%; dilute with 50&#8239;mL and give over 20 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <p>Desmopressin oral lyophilisates are for sublingual administration.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Hyponatraemic convulsions</h3>
              <p>Patients being treated for primary nocturnal enuresis should be warned to avoid fluid overload (including during swimming) and to stop taking desmopressin during an episode of vomiting or diarrhoea (until fluid balance normal).</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Desmopressin for bedwetting</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/desmopressin-bedwetting-0">www.medicinesforchildren.org.uk/desmopressin-bedwetting-0</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Asthma
          </li>
          <li>
            avoid fluid overload
          </li>
          <li>
            cardiovascular disease (not indicated for nocturnal enuresis or noctuira)
          </li>
          <li>
            conditions which might be aggravated by water retention
          </li>
          <li>
            cystic fibrosis
          </li>
          <li>
              <strong>:</strong>
            elderly (avoid for nocturnal enuresis and nocturia in those over 65 years) in adults
          </li>
          <li>
            epilepsy
          </li>
          <li>
            heart failure
          </li>
          <li>
            hypertension (not indicated for nocturnal enuresis or noctuira)
          </li>
          <li>
            migraine
          </li>
          <li>
            nocturia&#8212;limit fluid intake to minimum from 1 hour before dose until 8 hours afterwards
          </li>
          <li>
            nocturnal enuresis&#8212;limit fluid intake to minimum from 1 hour before dose until 8 hours afterwards
          </li>
        </ul>
        <ul>
          <li>
              <strong>With intranasal use:</strong>
            should not be given intranasally for nocturnal enuresis due to an increased incidence of side-effects
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>In <i>nocturia</i>, periodic blood pressure and weight checks are needed to monitor for fluid overload.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Consult product literature for individual preparations.</p><p>Not licensed for assessment of antidiuretic hormone secretion.</p><p>Oral use of <i>DDAVP</i> intravenous injection is not licensed.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Oral, intranasal, intravenous, subcutaneous and intramuscular doses are expressed as desmopressin acetate; sublingual doses are expressed as desmopressin base.</p><p>Children requiring an intranasal dose of less than 10&#8239;micrograms should be given <i>DDAVP</i>
            <tm tmtype="reg"/> intranasal solution.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of DESMOPRESSIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            spray,
            oral solution,
            capsule,
            nasal drops,

            <div id="PHP75072"><a href="../medicinalForm/PHP75072.html" data-target="#PHP75072" data-action="load">Tablet</a></div>
            <div id="PHP75123"><a href="../medicinalForm/PHP75123.html" data-target="#PHP75123" data-action="load">Oral solution</a></div>
            <div id="PHP75102"><a href="../medicinalForm/PHP75102.html" data-target="#PHP75102" data-action="load">Oral lyophilisate</a></div>
            <div id="PHP75091"><a href="../medicinalForm/PHP75091.html" data-target="#PHP75091" data-action="load">Solution for injection</a></div>
            <div id="PHP75097"><a href="../medicinalForm/PHP75097.html" data-target="#PHP75097" data-action="load">Spray</a></div>
            <div id="PHP75117"><a href="../medicinalForm/PHP75117.html" data-target="#PHP75117" data-action="load">Nasal drops</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
